Remove solutions phase-ii-iv clinical-data-management
article thumbnail

10 Trends and Statistics for Clinical Trials in 2023

XTalks

Clinical trials play a vital role in advancing patient treatment and medical care. This article delves into ten trends and statistics in the world of clinical trials for 2023. And don’t forget to explore the upcoming webinars about clinical trials on Xtalks to see what piques your curiosity about the latest clinical trial solutions.

article thumbnail

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Roche’s Chief Medical Officer and Head of Global Product Development. “As

HR 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Their large revenue growth from 2021 to 2022 can be attributed to several significant business development activities in 2022, predominantly acquisitions. For example, in March 2022, Pfizer acquired Arena, a clinical-stage company developing therapies for various immune-inflammatory diseases. billion in 2022. billion in 2022.

Sales 98
article thumbnail

COVID-19 Pandemic Coverage

XTalks

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial.

article thumbnail

XELJANZ® (TOFACITINIB CITRATE) RECEIVES MARKETING AUTHORIZATION IN THE EUROPEAN UNION.

The Pharma Data

Two formulations were approved, a tablet and a new oral solution (weight-based dosing). We are proud to make these new options available in the EU as Pfizer continues to advance the science and understanding of medicines like XELJANZ, which has been studied in more than 50 trials across clinical programs worldwide.”.